These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 372667)

  • 1. [Use of the aldosterone antagonist, canrenoate potassium for treating chronic circulatory insufficiency].
    Sidorenko BA; Kudisov IuM; Rossel's AN; Razumova ET
    Kardiologiia; 1979 Mar; 19(3):41-6. PubMed ID: 372667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic activity of potassium canrenoate in man.
    Yeh BK; Chiang BN; Sung PK
    Am Heart J; 1976 Sep; 92(3):308-14. PubMed ID: 949026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical use of pterofen as a diuretic agent in circulatory insufficiency].
    Liberman TIu
    Kardiologiia; 1976 Aug; 16(8):43-8. PubMed ID: 1011504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics of sodium and water elimination in chronic cardiac insufficiency].
    Somova LV; Bagrov IaI
    Kardiologiia; 1976 Aug; 16(8):58-63. PubMed ID: 1011505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.
    Armanini D; Scaroni C; Mattarello MJ; Fiore C; Albiger N; Sartorato P
    J Endocrinol Invest; 2005 Mar; 28(3):236-40. PubMed ID: 15952408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of cardiac glycosides of strophanthin-like action in the pharmacotherapy of chronic circulatory insufficiency].
    Leshchinskiĭ LA; Karbasnikova GV; Zabel'ian OM; Vasil'kova AA
    Kardiologiia; 1978 Mar; 18(3):76-83. PubMed ID: 347140
    [No Abstract]   [Full Text] [Related]  

  • 8. [Fluid redistribution between the extracellular medium and the cells in the diuretic therapy of cardiac insufficiency].
    Vinogradov AV; Sycheva IM; Zhuravleva IA
    Kardiologiia; 1975 Oct; 15(10):46-52. PubMed ID: 796532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of cardiac glycosides in chronic circulatory insufficiency].
    Sivkov II; Kukes VG
    Kardiologiia; 1975 Oct; 15(10):52-8. PubMed ID: 1234914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
    Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance.
    Girerd N; Aubry M; Lantelme P; Huttin O; Rossignol P
    Int Heart J; 2021 Jan; 62(1):193-196. PubMed ID: 33455988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.
    Minnaard-Huiban M; Emmen JM; Roumen L; Beugels IP; Cohuet GM; van Essen H; Ruijters E; Pieterse K; Hilbers PA; Ottenheijm HC; Plate R; de Gooyer ME; Smits JF; Hermans JJ
    Endocrinology; 2008 Jan; 149(1):28-31. PubMed ID: 17884944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with acute heart failure treated with the CARRESS-HF diuretic protocol in association with canrenoate potassium: Tolerance of high doses of canrenoate potassium.
    Berger C; Prieur C; Bochaton T; Berthiller J; Luyt CE; Bonnefoy-Cudraz E
    Arch Cardiovasc Dis; 2020 Nov; 113(11):679-689. PubMed ID: 32948466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of chronic cardiac insufficiency by combined use of adrenergic beta receptor blockaders and cardiac glycosides].
    Kedrov AA; Kedrova AN; Somova LV
    Klin Med (Mosk); 1978 Jan; 56(1):33-7. PubMed ID: 633796
    [No Abstract]   [Full Text] [Related]  

  • 16. Potassium canrenoate in the treatment of long-term digoxin-induced arrhythmias in conscious dogs.
    deGuzman NT; Yeh BK
    Am J Cardiol; 1975 Mar; 35(3):413-20. PubMed ID: 1114999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Digoxin treatment procedures and some ways to avoid glycoside poisoning].
    Kamenker SM
    Klin Med (Mosk); 1978 Oct; 56(10):68-74. PubMed ID: 713462
    [No Abstract]   [Full Text] [Related]  

  • 18. Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. A pilot study.
    Di Pasquale P; Cannizzaro S; Giubilato A; Vitrano MG; Scandurra A; Giambanco F; Saccone G; Sarullo FM; Paterna S
    Ital Heart J; 2001 Feb; 2(2):121-9. PubMed ID: 11256540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in water-salt metabolism in cardiac insufficiency under the influence of diuretic preparations].
    Sycheva IM; Vinogradov AV; Speranskaia NV; Krater AA; Ignatova TA
    Kardiologiia; 1973 Mar; 13(3):67-73. PubMed ID: 4780479
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis.
    Koda M; Murawaki Y; Kawasaki H; Ikawa S
    Hepatogastroenterology; 1996; 43(10):887-92. PubMed ID: 8884309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.